Compare GSK plc (GSK) vs Victoria's Secret & Co (VSXY) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

Victoria's Secret (VSXY) trades at $83.30, up 1.68% today, with a bullish technical outlook and strong analyst support. Recent earnings beats in Q3 2025 through Q1 2026 and a 44.9% international sales surge in Q1 2026 highlight operational momentum. The stock shows improving fundamentals with net income rising to $165 million in 2025 and a consensus price target of $88.56, suggesting 6% upside from current levels.

The outlook remains positive driven by international expansion and margin recovery, but risks include competitive pressures and reliance on consumer spending. With no sell ratings from analysts and institutional backing for the board, VSXY presents a growth opportunity with manageable risks for investors seeking apparel retail exposure.